Zinger Key Points
- House committee chairman Comer warns that the agency’s decision could lead to having dangerous products on the market.
- Therapeutic CBD products should be regulated as dietary supplements like fish oils, or melatonin, Rep. James Comer says.
- Feel unsure about the market’s next move? Copy trade alerts from Matt Maley—a Wall Street veteran who consistently finds profits in volatile markets. Claim your 7-day free trial now.
House Committee on Oversight and Accountability chairman James Comer announced the investigation into the Food and Drug Administration’s (FDA) failure to regulate cannabidiol (CBD) products as dietary supplements.
What Happened: After organizing a high-level internal working group to examine potential regulatory pathways for CBD products, the FDA concluded earlier this year it would not regulate it as a food and dietary supplement ingredient.
FDA deputy commissioner, Janet Woodcock said at the time that the agency will work with Congress to create "safeguards and oversight to manage and minimize risks related to CBD products,” reiterating controversial warnings that CBD poses risks to animals and that people could therefore be unknowingly exposed to it.
In a letter to FDA commissioner of food and drugs Dr. Robert M. Califf, Republican chair Comer warns that the agency’s decision could lead to having dangerous products on the market.
What Now: Comer is requesting documents and information to enable oversight of the FDA’s failure to provide Americans with regulatory guidance.
“The Committee on Oversight and Accountability is investigating the Food and Drug Administration’s (FDA) recent announcement regarding its authority to regulate CBD products as dietary supplements," Comer wrote. “The announcement states that the FDA does not believe its current regulatory framework allows for regulation of cannabidiols (CBD). The mission of the FDA is to advance[e] the public health by helping to ‘speed innovations that make medical products more effective, safer, and more affordable and by helping the public get the accurate, science-based information they need to use medical products and foods to maintain and improve their health.’ We seek documents and information to enable oversight of the FDA’s actions related to this announcement.”
In the letter, Comer also cited a recent report from the World Health Organization (WHO), which confirms that “across a number of controlled and open label trials of the potential therapeutic effects of CBD it is generally well tolerated, with a good safety profile.”
By not allowing therapeutic CBD products to be regulated as dietary supplements like fish oils, or melatonin, the good guys in the industry can’t enter the market and offer consumers with helpful products, Comer says. They are not distinguished under the FDA from “intoxicating products containing Delta-8.”
Photo: Benzinga edit with images by IRA_EVVA on Shutterstock and Zebulon Rogerson on Wikimedia Commons
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!